Home / Research library / Dihexa
Compound guide
Dihexa: what the research covers
A two-residue core wrapped in two lipophilic groups. The modifications are not incidental — they are what allow a peptide this small to reach the brain at all.
What Dihexa is
The full chemical name is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, which describes the molecule accurately: a tyrosine-isoleucine dipeptide carrying a hexanoic acid chain at one end and a hexylamide at the other. It derives from angiotensin IV, a fragment of the renin-angiotensin system with a cognitive literature quite separate from that system blood-pressure role.
The reported mechanism is potentiation of hepatocyte growth factor signalling at its receptor c-Met, rather than direct receptor agonism — that is, the compound is described as amplifying a signal that HGF is already producing. HGF and c-Met are implicated in synaptogenesis, which is the thread connecting the pharmacology to the behavioural findings.
The two lipophilic groups do the delivery work. An unmodified dipeptide would be cleaved in minutes and would not cross the blood-brain barrier; the acyl and alkyl additions confer both metabolic stability and lipophilicity, and published work reports oral activity in animals as a result.
Reading the evidence honestly
Dihexa attracts strong claims, and the evidence base does not support most of them. What exists is preclinical: rodent models of cognitive impairment, hippocampal spine density and synaptogenesis readouts, and in-vitro work on HGF and c-Met signalling. The reported potency figures in that literature are striking relative to the parent angiotensin IV fragment, which is why the compound became well known.
What does not exist is clinical data. There is no human trial literature, no established safety characterisation, and the mechanism — amplifying a growth factor pathway involved in proliferation — is one where the absence of long-term data is a substantive gap rather than a formality. A laboratory working with Dihexa is working at the preclinical frontier, and the honest framing of any result is that it is early.
Within this catalogue the closest comparisons are Semax and Selank, both of which have a longer research history and a much better characterised profile.
How Amino Club supplies it
Supplied lyophilised in sealed vials as Dihexa, specified at 99% purity or better by HPLC with identity confirmed by mass spectrometry and released against the batch Certificate of Analysis; the lab testing page documents the release sequence.
The lipophilic groups change the handling picture compared with an ordinary peptide: the molecule is poorly soluble in water and laboratories generally dissolve it in a co-solvent before dilution, which is a detail worth settling before the vial is opened. The powder is stable and stored below −18 °C. Solvent options are under reconstitution supplies.
Related reading
Dihexa sits in the cognitive and sleep research peptides group with Semax, Selank and DSIP. The comparison Semax versus Selank covers the two best-characterised members of that group.
Every guide is indexed in the research library. Certificates and storage are covered on the FAQ, quantity pricing through bulk and wholesale.
Research use only
Dihexa supplied by Amino Club is a laboratory reference material. It is not a medicine, not a supplement, and not for human or veterinary use, and no dosing guidance or administration protocol is provided. The full terms are in the research use policy.